Biological activities of p53 mutants in Burkitt's lymphoma cells.
Wild-type human p53 and a series of p53 point mutants isolated from Burkitt's lymphoma (BL) cell lines were tested for their ability to inhibit DNA synthesis in a p53-negative BL cell line and to bind and be degraded by the human papillomavirus type 16 E6 protein. All the mutants lost the wild-type ability to inhibit DNA synthesis, demonstrating that they are all functionally altered. Binding to E6 and consequent degradation of the p53 mutants frequently correlated with changed suppressor properties in BL cells.
Vousden
K H
KH
Ludwig Institute for Cancer Research, St Mary's Hospital Medical School, London, U.K.
Crook
T
T
Farrell
P J
PJ
D000818:Animals; D015153:Blotting, Western; D002051:Burkitt Lymphoma / Q000235:genetics*; D004273:DNA, Neoplasm / Q000096:biosynthesis; D006801:Humans; D009154:Mutation; D009856:Oncogene Proteins, Viral / Q000378:metabolism; D051381:Rats; D012097:Repressor Proteins; D014162:Transfection; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000235:genetics* / Q000378:metabolism
D004273:DNA, Neoplasm; C068651:E6 protein, Human papillomavirus type 16; D009856:Oncogene Proteins, Viral; D012097:Repressor Proteins; D016159:Tumor Suppressor Protein p53